Advaxis (NASDAQ: ADXS) is one of 183 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Advaxis to similar companies based on the strength of its earnings, profitability, institutional ownership, dividends, risk, analyst recommendations and valuation.
Volatility and Risk
Advaxis has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Advaxis’ competitors have a beta of 1.58, meaning that their average share price is 58% more volatile than the S&P 500.
Valuation and Earnings
This table compares Advaxis and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Advaxis||$3.99 million||-$73.55 million||-1.32|
|Advaxis Competitors||$217.30 million||-$39.39 million||-72.24|
Advaxis’ competitors have higher revenue and earnings than Advaxis. Advaxis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Advaxis and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
41.4% of Advaxis shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.2% of Advaxis shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current recommendations and price targets for Advaxis and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Advaxis presently has a consensus target price of $21.00, indicating a potential upside of 593.07%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.00%. Given Advaxis’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Advaxis is more favorable than its competitors.
Advaxis Company Profile
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.